Adicet Bio Inc. (ACET)
| Bid | 0.56 |
| Market Cap | 50.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -117.12M |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -0.46 |
| Forward PE | -0.44 |
| Analyst | Buy |
| Ask | 0.6 |
| Volume | 174,801 |
| Avg. Volume (20D) | 836,744 |
| Open | 0.59 |
| Previous Close | 0.58 |
| Day's Range | 0.58 - 0.62 |
| 52-Week Range | 0.45 - 2.08 |
| Beta | 1.64 |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...
Analyst Forecast
According to 7 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 874.03% from the latest price.
Stock Forecasts
3 weeks ago · businesswire.com
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
2 months ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
